Jurisdiction - Japan
Japan – Skadden Advises Miraca Holdings on USD725m Acquisition of Caris Life Sciences’ Anatomic Pathology Business.


12 October, 2011


Skadden is representing Miraca Holdings Inc., a Japanese healthcare and diagnostics services company and Japan’s largest clinical diagnostics and laboratory services provider, in its approximately US$725 million acquisition of the anatomic pathology business of Caris Life Sciences, Inc., a premier provider of anatomical pathology services to physicians and hospitals in the United States.  The molecular profiling and circulating microvesicle technology subsidiaries of Caris Life Sciences are to be retained by current shareholders and spun off immediately prior to the proposed merger with Miraca Holdings.  This is the first-ever acquisition by a Japanese company of a US clinical laboratory testing business, as well as Miraca Holdings’ largest acquisition to date.  The deal is scheduled to be closed toward the end of this year.


Skadden is also advising Miraca Holdings in approximately US$600 million of debt financing from three Japanese Mega banks in connection with the Caris acquisition.


The Skadden cross-border team, led by Tokyo partners Hiro KamiyaandMike Mies, includes, in Tokyo,Hajime Kanagawa,Justin Larson,and Tomoko Shimamura, corporate; in Palo Alto, Nels Hansen, corporate; Barbara Mirza, employee benefits and executive compensation; Kristin Major and Christy Peetz, labor and employment; and Carrie LeRoy, intellectual property and technology; in Los Angeles, Mike Beinus and Brett Willis, tax; in Hong Kong, Ed Sheremeta and, in Beijing, Wei Yang, real estate; in New York, Mike Zeideland Courtney Dinsmore, corporate finance; in Washington, D.C., Ken Gideon, tax; Jennifer Bragg and Nicole Grimm, health care enforcement and litigation; andBrian Mohr, antitrust.


For Further information, please contact:


Andrew Towler, Skadden

[email protected]




Leave a Reply

You must be logged in to post a comment.